While few stocks have escaped the broader market’s collapse in recent days and weeks, the author of today’s article notes that “there are a few investments that have been able to post big gains in the shadow of Covid-19’s spread.” In evidence of this, he proceeds to highlight a little-known ETF that, thanks to its particular investment objective, has been crushing it despite the broader coronavirus-driven collapse. For more, CLICK HERE.
With only 10% of drug candidates that reach the clinical trial stage eventually making their way onto the market, knowing which small biotechs to bet on for big gains is no easy feat for investors. The author of today’s article suggests that one way investors can increase their odds of success is by identifying small biotechs that are getting the attention (and money) of big pharma companies. He proceeds to highlight one such company, which “has developed an innovative product that makes other drugs more effective” – attracting capital from the likes of Roche, Johnson & Johnson and more. To read about this company, the science behind its technology – and the opportunity for investors – CLICK HERE.
While it may seem like no retailer is safe from being snuffed out by Amazon, the authors of today’s article show how investors can still make big gains in this sector using the “Amazon Survivors” Index – a compilation of retailers that one research firm believes can survive the serial killer that is Amazon. What is the (surprising) best-performing stock in this index right now – and how can investors use the index’s inclusions (as well as its exclusions) to generate big gains? CLICK HERE.